250 related articles for article (PubMed ID: 24072246)
1. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
2. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P; Lassalle M; Mercier G; Raquin MA; Izzi G; Corradini N; Hartmann O
J Pediatr Hematol Oncol; 2004 Oct; 26(10):649-55. PubMed ID: 15454836
[TBL] [Abstract][Full Text] [Related]
3. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
4. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
5. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens.
Dean JB; Hayashi SS; Albert CM; King AA; Karzon R; Hayashi RJ
J Pediatr Hematol Oncol; 2008 Feb; 30(2):130-4. PubMed ID: 18376265
[TBL] [Abstract][Full Text] [Related]
6. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
7. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
Lafay-Cousin L; Purdy E; Huang A; Cushing SL; Papaioannou V; Nettel-Aguirre A; Bouffet E
Pediatr Blood Cancer; 2013 Feb; 60(2):287-92. PubMed ID: 23002030
[TBL] [Abstract][Full Text] [Related]
8. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens.
Kolinsky DC; Hayashi SS; Karzon R; Mao J; Hayashi RJ
J Pediatr Hematol Oncol; 2010 Mar; 32(2):119-23. PubMed ID: 20098336
[TBL] [Abstract][Full Text] [Related]
9. [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Magy Onkol; 2006; 50(4):329-35. PubMed ID: 17216007
[TBL] [Abstract][Full Text] [Related]
10. Hearing loss in Mexican children treated with cisplatin.
Castelán-Martínez OD; Jiménez-Méndez R; Rodríguez-Islas F; Fierro-Evans M; Vázquez-Gómez BE; Medina-Sansón A; Clark P; Carleton B; Ross C; Hildebrand C; Castañeda-Hernández G; Rivas-Ruiz R
Int J Pediatr Otorhinolaryngol; 2014 Sep; 78(9):1456-60. PubMed ID: 25037447
[TBL] [Abstract][Full Text] [Related]
11. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach.
Orgel E; Jain S; Ji L; Pollick L; Si S; Finlay J; Freyer DR
Pediatr Blood Cancer; 2012 Jun; 58(6):953-8. PubMed ID: 21796767
[TBL] [Abstract][Full Text] [Related]
12. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Schornagel JH; Dreschler WA; Rasch CR; Balm AJ
J Clin Oncol; 2007 Aug; 25(24):3759-65. PubMed ID: 17704425
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
14. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
Yancey A; Harris MS; Egbelakin A; Gilbert J; Pisoni DB; Renbarger J
Pediatr Blood Cancer; 2012 Jul; 59(1):144-8. PubMed ID: 22431292
[TBL] [Abstract][Full Text] [Related]
16. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.
Knight KR; Kraemer DF; Neuwelt EA
J Clin Oncol; 2005 Dec; 23(34):8588-96. PubMed ID: 16314621
[TBL] [Abstract][Full Text] [Related]
17. Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors.
Clemens E; de Vries AC; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; Pluijm SF; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; Neggers SJ; van Grotel M; M van den Heuvel-Eibrink M
Pediatr Hematol Oncol; 2017 Mar; 34(2):120-129. PubMed ID: 28590156
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
19. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
20. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
Waissbluth S; Del Valle Á; Chuang A; Becker A
Int J Pediatr Otorhinolaryngol; 2018 Aug; 111():174-179. PubMed ID: 29958605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]